Gastroparesis Drugs Market Trends

Skyquest Technology's expert advisors have carried out comprehensive research on the gastroparesis drugs market to identify the major global and regional market trends and growth opportunities for leading players and new entrants in this market. The analysis is based on in-depth primary and secondary research to understand the major market drivers and restraints shaping the future development and growth of the industry.

Gastroparesis Drugs Market Dynamics

Gastroparesis Drugs Market Drivers

Increasing Prevalence of Diabetes and Related GI Disorders

  • A key driver for the market is the rising incidence of diabetes, which is closely linked to gastroparesis. As more individuals develop Type 1 and Type 2 diabetes globally, complications like diabetic gastroparesis are becoming more common, necessitating medical intervention. In January 2024, the International Diabetes Federation reported a noticeable uptick in global diabetic cases, especially in Asia and North America, pushing pharmaceutical companies like Evoke Pharma to ramp up production of drugs like Gimoti, targeting diabetic gastroparesis.

Advancements in Drug Delivery Technologies

  • Novel drug delivery systems, including nasal sprays and transdermal patches, are making treatment more patient-friendly, improving adherence, and expanding the market potential. In April 2024, Allay Therapeutics announced successful Phase II trials of its long-acting subcutaneous patch for gastroparesis, designed to release medication over an extended period, reducing the need for daily dosing.

Gastroparesis Drugs Market Restraints

Limited Efficacy of Existing Drugs

  • Many currently approved drugs for gastroparesis offer only symptomatic relief and often come with side effects, limiting long-term use and patient satisfaction. In April 2024, the FDA declined the approval of a novel prokinetic agent from PharmaNova due to inadequate long-term safety data. This setback reflects ongoing regulatory hurdles and emphasizes the difficulty of bringing new, safe therapies to market.

Regulatory and Safety Challenges

  • Gastroparesis drugs often face delays in approval due to concerns about cardiac and neurological side effects, making it difficult for new entrants to gain market traction. In June 2024, the FDA postponed approval of a new dopamine antagonist from a European company citing potential QT prolongation risks, stalling market expansion in the U.S.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Gastroparesis Drugs Market size was valued at USD 4.6 Billion in 2023 and is poised to grow from USD 4.81 Billion in 2024 to USD 6.9 Billion by 2032, growing at a CAGR of 4.6% in the forecast period (2025-2032).

The competitive landscape of the global gastroparesis drugs industry in 2024 is characterized by ongoing advancements in drug development, strategic collaborations, and an increasing focus on patient-centered treatments. Key players in the market, such as AbbVie, Boston Scientific, and Takeda Pharmaceuticals, are actively involved in the research and development of new therapies. 'AbbVie', 'Evoke Pharma', 'Vanda Pharmaceuticals', 'Renexxion Ireland Limited', 'Celerion', 'AstraZeneca', 'GSK (GlaxoSmithKline)', 'Ironwood Pharmaceuticals', 'Takeda Pharmaceutical', 'UCB Pharma', 'Valeant Pharmaceuticals', 'Progenics Pharmaceuticals', 'Meda AB (Acquired by Mylan)', 'Synergy Pharmaceuticals (Acquired by Bausch Health)', 'Mallinckrodt Pharmaceuticals'

A key driver for the market is the rising incidence of diabetes, which is closely linked to gastroparesis. As more individuals develop Type 1 and Type 2 diabetes globally, complications like diabetic gastroparesis are becoming more common, necessitating medical intervention. In January 2024, the International Diabetes Federation reported a noticeable uptick in global diabetic cases, especially in Asia and North America, pushing pharmaceutical companies like Evoke Pharma to ramp up production of drugs like Gimoti, targeting diabetic gastroparesis.

AI-Powered Drug Discovery and Trial Design: Artificial intelligence is becoming an integral part of pharmaceutical R&D, especially for complex disorders like gastroparesis, which lack a one-size-fits-all treatment. AI helps in identifying molecular targets, simulating drug interactions, and optimizing clinical trial protocols. In March 2024, Quris-AI collaborated with NeuroGasTx to streamline its gastroparesis clinical trial strategy using AI-powered patient simulation models. This reduced trial costs and increased enrollment efficiency by 25%, improving speed-to-market for their new neuromodulating drug.

What is Driving the Growth of the Gastroparesis Drugs Market in North America?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Gastroparesis Drugs Market
Gastroparesis Drugs Market

Report ID: SQMIG35I2378

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE